Literature DB >> 5368643

[Pharmacokinetics of meprobamate in chronic liver diseases and drug addiction].

H Held, H F von Oldershausen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 5368643     DOI： 10.1007/bf01745770

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


× No keyword cloud information.
  13 in total

1.  DIPHENYLHYDANTOIN AND PHENOBARBITAL TOXICITY. THE ROLE OF LIVER DISEASE.

Authors:  H KUTT; W WINTERS; R SCHERMAN; F MCDOWELL
Journal:  Arch Neurol       Date:  1964-12

2.  KINETICS OF MEPROBAMATE ELIMINATION IN HUMANS.

Authors:  L E HOLLISTER; G LEVY
Journal:  Chemotherapia (Basel)       Date:  1964

3.  Metabolism of drugs. 28. Metabolic fate of meprobamate. (1). Isolation and characterization of metabolites.

Authors:  A YAMAMOTO; H YOSHIMURA; H TSUKAMOTO
Journal:  Chem Pharm Bull (Tokyo)       Date:  1962-06       Impact factor: 1.645

4.  Induction of increased meprobamate metabolism in rats pretreated with some neurotropic drugs.

Authors:  R KATO; P VASSANELLI
Journal:  Biochem Pharmacol       Date:  1962-08       Impact factor: 5.858

5.  Colorimetric determination of meprobamate in biological fluids.

Authors:  B J LUDWIG; A J HOFFMAN
Journal:  Arch Biochem Biophys       Date:  1957-11       Impact factor: 4.013

6.  Determination and physiologic disposition of meprobamate.

Authors:  B W AGRANOFF; R M BRADLEY; J AXELROD
Journal:  Proc Soc Exp Biol Med       Date:  1957-10

7.  The effect of barbiturates in patients with liver disease.

Authors:  J T SESSIONS; H P MINKEL; J C BULLARD; F J INGELFINGER
Journal:  J Clin Invest       Date:  1954-08       Impact factor: 14.808

8.  Colorimetric determination of meprobamate in blood.

Authors:  O D MADSEN
Journal:  Clin Chim Acta       Date:  1962-07       Impact factor: 3.786

9.  Structures of the major metabolites of meprobamate.

Authors:  B J LUDWIG; J F DOUGLAS; L S POWELL; M MEYER; F M BERGER
Journal:  J Med Pharm Chem       Date:  1961-01-10

10.  [On the pharmacokinetics of sulfonamides in liver damage].

Authors:  H Held; L von Berger; H F von Oldershausen
Journal:  Verh Dtsch Ges Inn Med       Date:  1968
View more
  9 in total

1.  Carbamic acid esters of glycols.

Authors: 
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

2.  Effects of liver disease and of aging on the disposition and elimination of sedatives.

Authors:  S Schenker
Journal:  Trans Am Clin Climatol Assoc       Date:  1978

3.  [Changes in the velocity of drug catabolism and their importance in drug therapy].

Authors:  G F Kahl
Journal:  Klin Wochenschr       Date:  1971-04-01

4.  [Influence of liver diseases and kidney function disorders and phenylbutazone, phenprocoumarol and doxycycline on the excretion of glycodiazine].

Authors:  H Held; B Kaminski; H F von Oldershausen
Journal:  Diabetologia       Date:  1970-08       Impact factor: 10.122

5.  [The break-down of pentobarbital in hepatic diseases].

Authors:  H F von Oldershausen; H Held; H Remmer
Journal:  Klin Wochenschr       Date:  1970-05-01

6.  Determination of drug metabolizing enzymes in needle biopsies of human liver.

Authors:  B Schoene; R A Fleischmann; H Remmer; H F von Oldershausen
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

7.  Enhancement of hepatic drug metabolism by glutethimide in patients with liver disease.

Authors:  G C Farrell; W G Cooksley; L W Powell
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Polymorphic hydroxylation of perhexiline maleate in man.

Authors:  R G Cooper; D A Evans; E J Whibley
Journal:  J Med Genet       Date:  1984-02       Impact factor: 6.318

9.  Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.

Authors:  R R Shah; N S Oates; J R Idle; R L Smith; J D Lockhart
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.